RN
Before anything else, a correction to the premise most writing on this subject still carries.
HIV in 2026 is not what the phrase "HIV/AIDS" implies. With antiretroviral treatment it is a manageable chronic condition with a normal life expectancy, and a person on effective treatment with a sustained undetectable viral load does not transmit it sexually. That is not optimism or advocacy phrasing; it is the settled position of every major public health body, established by large trials and known in shorthand as U=U. Pre-exposure prophylaxis, taken by an HIV-negative person, is separately and highly effective at preventing acquisition.
None of that was true in the same way when the events below happened, and none of it makes an occupational transmission acceptable. But an article that describes a diagnosis as a career-ending catastrophe and a "deadly disease" is describing 1995, and the people living with it are the ones who pay for that framing being kept in circulation.
April 2004
In April 2004 an American performer, Darren James, tested positive. He had tested negative shortly before, and the conclusion investigators reached was that the infection occurred during a shoot abroad, in Brazil, in the window between tests.
The problem was what happened in that window. He continued working after the exposure and before the positive result, and by the time it surfaced three other performers had been infected. Contact tracing pulled in a much wider group — around fifty people were identified as having had direct or second-degree exposure — and most of the American industry stopped shooting while they were tested.
James spoke publicly about it afterwards, repeatedly and at length. So did Lara Roxx, the Canadian performer who was the newest to the industry of anyone involved, and who has since described the circumstances of the shoot, the pressure around it, and what followed, including in a documentary she took part in. Their accounts are on the record because they chose to put them there.
The two other people who tested positive in that cluster were named in press coverage at the time. They did not put their status on the record themselves and have not spoken about it since. They are not named here, and the earlier version of this article should not have named them either.
What 2004 changed
The industry had run performer testing since the late 1990s on a thirty-day cycle. The 2004 cluster demonstrated the obvious flaw: a thirty-day window is a very long time to be working while infected and undetected.
What emerged over the following years, eventually consolidated as PASS, tightened the interval to fourteen days, standardised which panel is run, restricted testing to certified facilities, and — the part that matters most and gets discussed least — built a shared clearance database with contact tracing, so a positive result triggers a traceable response rather than a rumour.
It is a real system and it works considerably better than nothing. It also has a structural limit that no amount of frequency removes. Testing is retrospective. It tells you about a past moment, and depending on the test used there is a window after infection during which it will return negative regardless. A performer can be genuinely, correctly cleared and infectious on the same day. Every argument about testing intervals is really an argument about how large a residual risk is acceptable, and there is no interval at which the residual becomes zero.
2013
Nine years later there were multiple production halts inside a single year. Two performers, Cameron Bay and Rod Daily, disclosed their positive results publicly — Daily announced his on Twitter himself — and both became visible advocates for changing how the industry handled safety.
The source of those infections was never publicly established, which is worth stating plainly rather than assuming. "Contracted on the job" is the framing the headline of this article uses, and it was demonstrated for the 2004 cluster. For 2013 it was asserted by some and disputed by others and never resolved, and performers have private lives like everyone else.
One of that year's moratoria was called on a result that turned out to be a false positive. That is not a small footnote — it is a reminder that a single test is a probability statement, and that the system's response to one is necessarily precautionary.
The condom fight
The AIDS Healthcare Foundation spent the following decade pushing to make barrier use mandatory rather than optional. Los Angeles County voters passed Measure B in 2012, requiring condoms on shoots covered by county permits. Production largely responded by filing permits elsewhere.
The statewide version, Proposition 60, went to California voters in November 2016 and lost by roughly 54 to 46. The industry's campaign against it ran on two arguments: that mandated condoms would push production underground and out of the testing system entirely, and that a provision allowing private enforcement suits exposed individual performers to being sued and to having their legal names entered into public court records. Performers themselves were prominent in opposing it, which is the detail that decided the outcome and that both sides' summaries tend to skip.
Underneath the campaigning is a genuine disagreement with no clean answer. Barriers reduce transmission risk directly and testing does not. Testing catches infections that barriers miss and covers acts barriers do not. Framing it as a choice between them was always the wrong question, and it remains unresolved rather than settled.
What is actually true now
Transmission on regulated sets is rare, and it is rare because of a combination — frequent testing, contact tracing, shared clearance records, wide PrEP uptake, and treatment that suppresses viral load to non-transmissible levels in people who are positive. No single one of those is doing the work.
None of it applies to production outside those systems, which is a substantial and growing share of what gets made now that anyone with a phone can shoot and sell. Independent and platform-based performers have no clearance database, no mandatory panel and no moratorium mechanism, and the safety infrastructure this article describes is largely invisible to them.
And a diagnosis today is a medical event with a treatment pathway, not the ending the older coverage implied. Several of the people in this story are still alive and were still working years afterwards.
If any of this is a live question for you: testing is free or low-cost through public sexual health services in most countries, PrEP is available on prescription and widely subsidised, and post-exposure prophylaxis works if started quickly — hours matter. A clinician can tell you what applies to your situation. This article cannot.